CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies

[1]  M. Churchill,et al.  HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research , 2015, Journal of NeuroVirology.

[2]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[3]  Sarah Palmer,et al.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. , 2014, The lancet. HIV.

[4]  Sonia Shah,et al.  Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I , 2014, Virology Journal.

[5]  R. Siliciano,et al.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Churchill,et al.  Where does HIV hide? A focus on the central nervous system , 2013, Current opinion in HIV and AIDS.

[7]  Qiang Zhou,et al.  The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation , 2012, Nucleic acids research.

[8]  M. Churchill,et al.  Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. , 2012, AIDS research and human retroviruses.

[9]  S. Deeks.  HIV: Shock and kill , 2012, Nature.

[10]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[11]  I. Sadowski,et al.  The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV‐1 without producing a T cell response , 2011, FEBS letters.

[12]  Sonia Shah,et al.  Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage , 2009, Retrovirology.

[13]  Nirav Malani,et al.  HIV integration site distributions in resting and activated CD4+ T cells infected in culture , 2009, AIDS.

[14]  M. Churchill,et al.  Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain , 2009, Journal of Virology.

[15]  Priya S. Shah,et al.  Control of Stochastic Gene Expression by Host Factors at the HIV Promoter , 2009, PLoS pathogens.

[16]  D. Margolis,et al.  Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. , 2008, The Journal of infectious diseases.

[17]  Amy S. Espeseth,et al.  c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter , 2007, Journal of Virology.

[18]  Steven Wolinsky,et al.  High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-associated dementia. , 2007, AIDS research and human retroviruses.

[19]  Steven Wolinsky,et al.  Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. , 2007, Virology.

[20]  F. Dequiedt,et al.  Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencing , 2007, The EMBO journal.

[21]  A. Knezevich,et al.  Suv39H1 and HP1γ are responsible for chromatin‐mediated HIV‐1 transcriptional silencing and post‐integration latency , 2007, The EMBO journal.

[22]  Eric Verdin,et al.  The SWI/SNF Chromatin-remodeling Complex Is a Cofactor for Tat Transactivation of the HIV Promoter* , 2006, Journal of Biological Chemistry.

[23]  M. Churchill,et al.  Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues , 2006, Journal of NeuroVirology.

[24]  E. Verdin,et al.  NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.

[25]  F. Kashanchi,et al.  Tat gets the "green" light on transcription initiation , 2005, Retrovirology.

[26]  C. Van Lint,et al.  COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells , 2005, Nucleic acids research.

[27]  Paola Arlotta,et al.  Neuronal Subtype-Specific Genes that Control Corticospinal Motor Neuron Development In Vivo , 2005, Neuron.

[28]  M. Churchill,et al.  Astrocyte specific viral strains in HIV dementia , 2004, Annals of neurology.

[29]  A. L. Remoli,et al.  Role of Acetylases and Deacetylase Inhibitors in IRF‐1‐Mediated HIV‐1 Long Terminal Repeat Transcription , 2004, Annals of the New York Academy of Sciences.

[30]  P. Dollé,et al.  CTIP1 and CTIP2 are differentially expressed during mouse embryogenesis. , 2004, Gene expression patterns : GEP.

[31]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[32]  L. Penn,et al.  Repression of the human immunodeficiency virus type‐1 long terminal repeat by the c‐Myc oncoprotein , 2004, Journal of cellular biochemistry.

[33]  B. Korber,et al.  Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS , 2003, Journal of Virology.

[34]  V. Kiermer,et al.  Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. , 2003, Molecular cell.

[35]  Kuan-Teh Jeang,et al.  Tat and Trans-activation-responsive (TAR) RNA-independent Induction of HIV-1 Long Terminal Repeat by Human and Murine Cyclin T1 Requires Sp1* , 2003, The Journal of Biological Chemistry.

[36]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[37]  D. Margolis,et al.  Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat , 2002, Molecular and Cellular Biology.

[38]  M. Churchill,et al.  c-Myb influences HIV type 1 gene expression and virus production. , 2001, AIDS research and human retroviruses.

[39]  E. De Clercq,et al.  Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity , 2001, Journal of Virology.

[40]  A. Jordan,et al.  The site of HIV‐1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation , 2001, The EMBO journal.

[41]  B. Brew,et al.  Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): evidence for neurotropic HIV variants. , 2001, Virology.

[42]  B. Wigdahl,et al.  Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication. , 2000, Virology.

[43]  E. Wintersberger,et al.  Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1 , 1999, Molecular and Cellular Biology.

[44]  M. Giacca,et al.  HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Grant,et al.  Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Garl,et al.  HIV-1 LTR DNA sequence variation in brain-derived isolates. , 1997, Journal of neurovirology.

[47]  R. Gaynor,et al.  In Vitro Chromatin Assembly of the HIV-1 Promoter , 1997, The Journal of Biological Chemistry.

[48]  D. Richman,et al.  In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues , 1997, Journal of virology.

[49]  J. Clements,et al.  In vivo transcriptional regulation of the human immunodeficiency virus in the central nervous system in transgenic mice , 1996, Journal of virology.

[50]  D. Aunis,et al.  Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells , 1995, Journal of virology.

[51]  M. Garcia-Blanco,et al.  Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat , 1995, Journal of virology.

[52]  J. Clements,et al.  HIV-1 in the developing CNS: developmental differences in gene expression. , 1995, Virology.

[53]  Margaret A. Johnson,et al.  Distinct HIV‐1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient , 1995, AIDS.

[54]  R. Roeder,et al.  Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators , 1995, Science.

[55]  B. Franza,et al.  In vitro study of functional involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol 12-myristate 13-acetate-mediated HIV-1 long terminal repeat activation. , 1994, The Journal of biological chemistry.

[56]  B. Korber,et al.  Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences , 1994, Journal of virology.

[57]  A. Emili,et al.  Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. , 1994, Molecular and cellular biology.

[58]  D. Margolis,et al.  Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production , 1994, Journal of virology.

[59]  J. Clements,et al.  Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice. , 1992, Science.

[60]  P. Andrews,et al.  Differentiation-dependent human immunodeficiency virus long terminal repeat regulatory elements active in human teratocarcinoma cells , 1992, Journal of virology.

[61]  E. Major,et al.  Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta , 1991, Journal of virology.

[62]  M. Martin,et al.  Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types , 1991, Journal of virology.

[63]  C. Kufta,et al.  Specific tropism of HIV-1 for microglial cells in primary human brain cultures. , 1990, Science.

[64]  D Harrich,et al.  Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat , 1989, Journal of virology.

[65]  M. Siekevitz,et al.  Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. , 1987, Science.

[66]  H. Vinters,et al.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.

[67]  R. Tjian,et al.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. , 1986, Science.

[68]  J. Sodroski,et al.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat , 1985, Cell.

[69]  E. Major,et al.  Establishment of a line of human fetal glial cells that supports JC virus multiplication. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[70]  G. Bornkamm,et al.  Characterization of EBV‐genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non‐Hodgkin lymphoma , 1977, International journal of cancer.